Posted by Michael Wonder on 08 Apr 2021
ICER to assess treatment for hypertrophic cardiomyopathy
8 April 2021 - Report will be subject of CTAF meeting in October 2021; draft scoping document open to public comment until 29 April 2021.
The Institute for Clinical and Economic Review announced today that it will assess the comparative clinical effectiveness and value of mavacamten (MyoKardia and Bristol-Myers Squibb) for the treatment of hypertrophic cardiomyopathy.
An FDA decision on mavacamten is expected in mid to late 2021.
